
Hans Bishop, CEO and Co-founder of Juno Therapeutics who helped set up the company in 2013 and has since grown …

Celgene has already started off the year with a bang, announcing a deal with Impact Biomedicines worth a potential $7 …

Just last week Novartis revealed it had applied to the FDA for a new indication in diffuse large B-cell lymphoma …

Celgene has invested $1 billion into Juno Therapeutics as part of a 10-year partnership aiming to study cures for cancer …

AstraZeneca posted a 1% increase in revenue in its first-quarter 2015 financials – and is investing the money to back …
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer

